Matched case control study investigating the association between HLA alleles and severe cutaneous adverse reactions suspected of being the effect of Atezolizumab

Matched case control study investigating the association between HLA alleles and severe cutaneous adverse reactions suspected of being the effect of Atezolizumab - Matched case control study investigating the association between HLA alleles and severe cutaneous adverse reactions suspected of being the effect of Atezolizumab (CMA-0173)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048702

Enrollment

Registered

2022-08-19

Start date

2022-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who develop a severe cutaneous adverse reaction (SCAR) after receiving treatment with atezolizumab in actual clinical practice (including clinical research other than a clinical study) (2) Patients who provide their informed consent in writing for participation in this study. (3) Aged at least 18 years old when consent is obtained (4) Patients who are able to provide samples (blood, etc.) for the HLA allele tests.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Presence of previously selected, identified HLA alleles	—

Secondary

Measure	Time frame
Genetic predisposition associated with the occurrence of a SCAR	—

Countries

Japan

Contacts

Public ContactHideki Masai

SRL Medisearch Inc. Clinical Research Div.

hideki.masai@hugp.com050-2000-5231

Outcome results